Balancing Efficacy, Tolerability, and Drug Monitoring in Schizophrenia Treatment

In "Balancing Efficacy, Tolerability, and Drug Monitoring in Schizophrenia Treatment," our panel explores two interconnected clinical priorities: the underutilization of therapeutic drug monitoring and the need to reframe how clinicians weigh efficacy against tolerability over the long term.

Dr. John Kane opens by highlighting the significant variability in how individual patients metabolize medications, and argues that long-acting injectable and transdermal formulations offer a more reliable relationship between dose and achieved plasma levels compared to oral agents. He notes that these delivery systems also reduce peak-to-trough variability and provide a more gradual decline in drug levels if doses are missed or discontinued. Drawing on two compelling research examples — an emergency department study in which clinicians incorrectly assessed adherence status in both directions, and a London clinic study in which approximately one-third of patients referred as putative treatment-resistant cases were found to have sub-therapeutic drug levels — Dr. Kane makes a strong case for routine therapeutic drug monitoring as an essential but underused clinical tool.

Dr. Christoph Correll then reframes the efficacy-versus-tolerability question, arguing that clinicians should not treat these as competing priorities to be resolved in a single decision, but rather as factors to be continuously monitored and re-evaluated across the patient's illness trajectory. He emphasizes the importance of understanding each patient's individual goals — which may extend well beyond symptom reduction to encompass housing, employment, social connection, and physical health — and incorporating those goals into treatment planning. He also highlights the subjective dimension of tolerability, noting that while side effect profiles can be predicted at a population level, individual patient experience varies considerably. Residual side effects such as tardive dyskinesia or cognitive dulling can undermine both functioning and adherence, making it essential to monitor their impact over time. Dr. Correll closes by introducing the concept of medication interest — a reframing of adherence that centers on whether patients perceive a meaningful personal benefit from their treatment relative to its burden — as the ultimate lens through which efficacy, safety, and adherence should be understood together.

Our next episode, "Recognizing Early Warning Signs of Relapse in Schizophrenia," examines the early warning signs of psychotic relapse that clinicians should monitor between visits, highlighting the practical tools, collateral communication strategies, and proactive outreach systems that help detect symptom changes before full decompensation occurs.